Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor - PubMed (original) (raw)
Case Reports
. 2001 Apr 5;344(14):1052-6.
doi: 10.1056/NEJM200104053441404.
Affiliations
- PMID: 11287975
- DOI: 10.1056/NEJM200104053441404
Free article
Case Reports
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
H Joensuu et al. N Engl J Med. 2001.
Free article
No abstract available
Similar articles
- [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
Guilhot F. Guilhot F. Bull Cancer. 2001 Jul;88(7):659-60. Bull Cancer. 2001. PMID: 11495817 French. No abstract available. - Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor.
Sawaki A, Ohashi K, Yamao K, Inada K, Shimizu Y, Matsuura A, Nakamura T, Suzuki T, Hara K, Okubo K, Ohno R. Sawaki A, et al. J Gastroenterol. 2003;38(7):690-4. doi: 10.1007/s00535-002-1124-1. J Gastroenterol. 2003. PMID: 12898363 - [A patient with metastatic gastrointestinal stromal tumor who responded to STI571].
Terashima M, Abe K, Takeda Y, Saito K, Uesugi N, Kato K, Sato K, Maekawa T. Terashima M, et al. Gan To Kagaku Ryoho. 2002 Apr;29(4):607-10. Gan To Kagaku Ryoho. 2002. PMID: 11977548 Japanese. - Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ. Druker BJ. Oncogene. 2002 Dec 9;21(56):8541-6. doi: 10.1038/sj.onc.1206081. Oncogene. 2002. PMID: 12476300 Review. No abstract available. - [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
Des Guetz G, De Mestier P, Pierga JY. Des Guetz G, et al. J Chir (Paris). 2002 Oct;139(5):268-73. J Chir (Paris). 2002. PMID: 12410126 Review. French.
Cited by
- Two different mutational types of familial gastrointestinal stromal tumors: Two case reports.
Wang XK, Shen LF, Yang X, Su H, Wu T, Tao PX, Lv HY, Yao TH, Yi L, Gu YH. Wang XK, et al. World J Gastrointest Oncol. 2024 Sep 15;16(9):4028-4036. doi: 10.4251/wjgo.v16.i9.4028. World J Gastrointest Oncol. 2024. PMID: 39350996 Free PMC article. - Incidence and Survival Outcomes of Gastrointestinal Stromal Tumors.
Alvarez CS, Piazuelo MB, Fleitas-Kanonnikoff T, Ruhl J, Pérez-Fidalgo JA, Camargo MC. Alvarez CS, et al. JAMA Netw Open. 2024 Aug 1;7(8):e2428828. doi: 10.1001/jamanetworkopen.2024.28828. JAMA Netw Open. 2024. PMID: 39158910 Free PMC article. - Advances in immunotherapy of M2 macrophages and gastrointestinal stromal tumor.
Wang XK, Yang X, Yao TH, Tao PX, Jia GJ, Sun DX, Yi L, Gu YH. Wang XK, et al. World J Gastrointest Oncol. 2024 Jul 15;16(7):2915-2924. doi: 10.4251/wjgo.v16.i7.2915. World J Gastrointest Oncol. 2024. PMID: 39072184 Free PMC article. Review. - RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor.
Zhang L, Zhang S, Cao X, Shi J, Zhao S, Tian J, Xiao K, Wang M, Liu J, Wang C, Zhou L, Yu Y, Zhao H, Li S, Sun J. Zhang L, et al. Oncogene. 2024 Jun;43(27):2078-2091. doi: 10.1038/s41388-024-03063-8. Epub 2024 May 17. Oncogene. 2024. PMID: 38760447 - Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?
Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Thirasastr P, et al. Cancers (Basel). 2024 Feb 23;16(5):904. doi: 10.3390/cancers16050904. Cancers (Basel). 2024. PMID: 38473266 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical